Loading
Anlotinib is one of the most used cancer pills in China, first approved for lung cancer after other treatments have failed and then for several rarer tumours.
Developed by Chia Tai Tianqing (Sino Biopharm); approved by the NMPA in May 2018 for advanced NSCLC after at least two lines on ALTER 0303 (439 patients: median overall survival 9.6 versus 6.3 months with placebo, hazard ratio 0.68), then for soft tissue sarcoma (2019), small cell lung cancer after two lines (2019) and medullary thyroid cancer (2020), with a string of combination trials alongside domestic PD-1 antibodies. Its wide use reflects NRDL listing from 2018 and a large domestic sales force as much as its effect size.
Oral inhibitor of VEGFR1-3, FGFR1-4, PDGFR alpha and beta, and KIT, blocking angiogenesis and tumour cell proliferation. Connects to VEGF / VEGFR, FGFR2 and KIT.
1.Anlotinib slips into a pocket on VEGF / VEGFR.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| China | 2018 | Advanced NSCLC after at least two lines of systemic therapy (ALTER 0303) |
| China | 2019 | Advanced soft tissue sarcoma after chemotherapy; small cell lung cancer after at least two lines |
| China | 2020 | Advanced medullary thyroid cancer |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Anlotinib" OR ABSTRACT:"Anlotinib" OR TITLE:"Focus V" OR ABSTRACT:"Focus V" OR TITLE:"AL3818" OR ABSTRACT:"AL3818" OR TITLE:"Catequentinib" OR ABSTRACT:"Catequentinib" OR TITLE:"Qezzaqar" OR ABSTRACT:"Qezzaqar") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Anlotinib, not a curated reading list.
Shares VEGF angiogenesis, VEGF / VEGFR, Thyroid cancer, Anti-angiogenic therapy and the tag china.
Shares Ying Cheng, Small-cell lung cancer and the tag china.
Shares VEGF angiogenesis, VEGF / VEGFR, Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag china.
Shares Ying Cheng, Small-cell lung cancer and the tag china.
Shares mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer, Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer, Non-small-cell lung cancer and the tag china.
Shares VEGF / VEGFR, Non-small-cell lung cancer and the tag china.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.